for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneron Pharmaceuticals Inc

REGN.N

Latest Trade

537.95USD

Change

0.91(+0.17%)

Volume

1,225

Today's Range

537.15

 - 

538.49

52 Week Range

441.16

 - 

663.47

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
537.04
Open
538.11
Volume
1,225
3M AVG Volume
17.18
Today's High
538.49
Today's Low
537.15
52 Week High
663.47
52 Week Low
441.16
Shares Out (MIL)
106.54
Market Cap (MIL)
57,097.50
Forward P/E
11.08
Dividend (Yield %)
--

Next Event

Regeneron Pharmaceuticals Inc at BMO Biopharma Day: Spotlight on Rare Disease and Ophthalmology (Virtual)

Latest Developments

More

FDA Authorizes Lower Dose Of Regen-Cov Antibody Cocktail To Treat COVID-19

Libtayo (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers

Regeneron Reports Q1 Non-Gaap Earnings Per Share $9.89

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Industry

Biotechnology & Drugs

Contact Info

777 Old Saw Mill River Rd

TARRYTOWN, NY

10591-6717

United States

+1.914.8477000

https://www.regeneron.com/

Executive Leadership

P. Roy Vagelos

Chairman of the Board

Leonard S. Schleifer

President, Chief Executive Officer, Founder, Director

George D. Yancopoulos

President, Chief Scientific Officer, Director

Robert E. Landry

Chief Financial Officer, Executive Vice President - Finance

Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

Key Stats

2.00 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

6.7K

2019

7.9K

2020

8.5K

2021(E)

12.2K
EPS (USD)

2018

22.840

2019

24.670

2020

31.470

2021(E)

47.258
Price To Earnings (TTM)
15.16
Price To Sales (TTM)
6.21
Price To Book (MRQ)
4.77
Price To Cash Flow (TTM)
13.43
Total Debt To Equity (MRQ)
22.52
LT Debt To Equity (MRQ)
16.52
Return on Investment (TTM)
28.34
Return on Equity (TTM)
23.88

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up